Stock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades

Stock Track

02-27

Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.

On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.

Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their "Buy" ratings on JAZZ.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1104802830"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104802830\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1104802830?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104802830","market":"hk","top_or_hot":-1,"title":"Stock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades","media":"Stock Track","content":"<p>Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.</p>\n\n<p>On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.</p>\n\n<p>Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their \"Buy\" ratings on JAZZ.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.</p>\n\n<p>On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.</p>\n\n<p>Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their \"Buy\" ratings on JAZZ.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1104802830","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104802830","pubTimestamp":1740589020,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Jazz Pharmaceuticals  stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and ea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票赛道Jazz Pharmaceuticals因盈利积极和分析师上调评级而飙升5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.\nOn Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.\nFollowing the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their \"Buy\" ratings on JAZZ.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}